Neurogene reports Q1 net loss of $22.6M; cash $292.6M; NGN-401 trial on track

Neurogene Inc.

2025-Q1 EPS reported -$1.08

Net loss of $22.6M for Q1 2025 vs $16.9M Q1 2024; R&D expenses rose to $17.8M from $13.5M.
Cash, equivalents and short-term investments of $292.6M as of March 31, 2025; runway into H2 2027.
NGN-401 gene therapy for Rett syndrome: registrational trial plan update expected in H1 2025; interim clinical data in H2 2025.
Enrolling additional participants in Phase 1/2 trial; pediatric cohort (age 4-10, N=8) and older cohort (11+, N=3).
Peer-reviewed publication in Science Translational Medicine validating EXACT transgene regulation technology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.